Original articlesThoracic tumorsEditor's ChoiceImpact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Thoracic tumors
Editor's Choice
Under a Creative Commons license
open access
Key words
ALK-rearranged NSCLC
sequential ALK-inhibitor therapy
TP53 mutation status
Cited by (0)
- †
A. Kron and C. Alidousty authors contributed equally to this work.
- ‡
A. M. Schultheis, R. Büttner and J. Wolf authors share senior authorship.
Data presented in part at the European Society of Medical Oncology Annual Meeting 2017, Madrid, Spain (abstract #3757) and the German Society of Hematology/Oncology Annual Meeting 2017, Stuttgart, Germany (abstract A-908-0026-00596).
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd.